Noxopharm Limited Stock Performance
| NOXOF Stock | USD 0.03 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Noxopharm are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Noxopharm Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Noxopharm is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 26.8 M |
Noxopharm |
Noxopharm Relative Risk vs. Return Landscape
If you would invest 3.00 in Noxopharm Limited on January 26, 2024 and sell it today you would earn a total of 0.00 from holding Noxopharm Limited or generate 0.0% return on investment over 90 days. Noxopharm Limited is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Noxopharm, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Noxopharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Noxopharm's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Noxopharm Limited, and traders can use it to determine the average amount a Noxopharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NOXOF |
Based on monthly moving average Noxopharm is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Noxopharm by adding Noxopharm to a well-diversified portfolio.
Noxopharm Fundamentals Growth
Noxopharm Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Noxopharm, and Noxopharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Noxopharm Pink Sheet performance.
| Return On Equity | -0.58 | |||
| Return On Asset | -0.16 | |||
| Operating Margin | (1.80) % | |||
| Current Valuation | 22.3 M | |||
| Shares Outstanding | 292.24 M | |||
| Price To Book | 2.36 X | |||
| Price To Sales | 7.11 X | |||
| Revenue | 5.43 M | |||
| EBITDA | (18.33 M) | |||
| Cash And Equivalents | 14.01 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 160.62 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (13.73 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 26.59 M | |||
About Noxopharm Performance
To evaluate Noxopharm Limited Pink Sheet as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Noxopharm generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Noxopharm Pink Sheet's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Noxopharm Limited market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Noxopharm's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. The company was incorporated in 2015 and is based in Chatswood, Australia. Noxopharm operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Noxopharm Limited performance evaluation
Checking the ongoing alerts about Noxopharm for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Noxopharm Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Noxopharm Limited generated a negative expected return over the last 90 days | |
| Noxopharm Limited has some characteristics of a very speculative penny stock | |
| Noxopharm Limited has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 5.43 M. Net Loss for the year was (18.67 M) with loss before overhead, payroll, taxes, and interest of (2.35 M). | |
| Noxopharm Limited has accumulated about 14.01 M in cash with (13.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 34.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Noxopharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Noxopharm's stock is overvalued or undervalued compared to its peers.
- Examining Noxopharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Noxopharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Noxopharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Noxopharm's pink sheet. These opinions can provide insight into Noxopharm's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Noxopharm Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Noxopharm Pink Sheet analysis
When running Noxopharm's price analysis, check to measure Noxopharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Noxopharm is operating at the current time. Most of Noxopharm's value examination focuses on studying past and present price action to predict the probability of Noxopharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Noxopharm's price. Additionally, you may evaluate how the addition of Noxopharm to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |